On July 8, 2011, Pfizer filed a pleading in the MDL Proceedings (4:03-cv-1507) asserting that there may be no reason for core discovery to take place in the MDL proceedings thereby permitting many cases to be remanded to the trial court for scheduling orders with trial dates. This development may be significant for the thousands of cases in the MDL proceeding.
Cases ripe for remand will involve those cases where only Wyeth/Upjohn are named as parties and those cases that are not subject to Daubert Motions pending in the MDL.
Attorneys for both sides of this litigation view this development to be significant in moving this slowed litigation forward. As many are aware this litigation started with the release of the Women’s Health Initiative in July, 2002.
For updates on the Prempro litigation check our blog for up-to-date information.